PTC Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PTC Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $3.12M, a 3.38% decline year-over-year.
- PTC Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- PTC Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $2.83M, a 43.28% increase year-over-year.
- PTC Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $0.00.
- PTC Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $5.94M, a 14.33% increase from fiscal 2024.
- PTC Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $5.20M, a 12.68% decline from fiscal 2023.
- PTC Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $5.95M, a 7.69% decline from fiscal 2022.
- PTC Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $6.45M, a 11.36% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2025-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $5.94M 10-K · filed 2026-02-19 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $6.05M derived: sum of 4 quarters · filed 2026-02-19 |
| 2025-06-30 | $2.83M 10-Q · filed 2025-08-07 | $6.05M derived: sum of 4 quarters · filed 2026-02-19 |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-02-19 | $5.20M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-12-31 | $3.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $5.20M 10-K · filed 2026-02-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | |
| 2024-06-30 | $1.97M 10-Q · filed 2025-08-07 | |
| 2023-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $5.95M 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-06-30 | $3.81M 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $6.45M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | |
| 2022-06-30 | $3.11M 10-Q · filed 2023-08-03 | |
| 2021-12-31 | $3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $5.79M 10-K · filed 2024-02-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | |
| 2021-06-30 | $2.63M 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $5.30M 10-K · filed 2023-02-21 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | |
| 2020-06-30 | $2.41M 10-Q · filed 2021-07-29 | |
| 2019-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $3.58M 10-K · filed 2022-02-22 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | |
| 2019-06-30 | $1.56M 10-Q · filed 2020-08-05 | |
| 2018-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.79M 10-K · filed 2021-02-25 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | |
| 2018-06-30 | $1.30M 10-Q · filed 2019-08-06 | |
| 2017-12-31 | $2.47M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |